<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237012</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB Protocol # 20192595</org_study_id>
    <nct_id>NCT04237012</nct_id>
  </id_info>
  <brief_title>ACCURATE Study for Subjects With Dry Eyes</brief_title>
  <acronym>ACCURATE</acronym>
  <official_title>Randomized Self-Controlled Treatment With an Intracanalicular Dexamethasone Insert Compared to Topical Over the Counter Lubrication Therapy in Patients With Bilateral Ocular Surface Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Eye Centers of Racine and Kenosha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Eye Centers of Racine and Kenosha</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine treatment and imaging outcomes in bilateral ocular surface disease management&#xD;
      with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical&#xD;
      over-the-counter artificial tears lubrication management&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the benefit of treatment with a physician administered&#xD;
      intracanalicular dexamethasone insert and patient administered artificial tears prn compared&#xD;
      to patient administered artificial tears prn (control) in patients with bilateral ocular&#xD;
      surface dry eye disease. The study is a self-controlled design and includes multiple&#xD;
      objective, measureable, and quantifiable endpoints to best determine an objective response to&#xD;
      treatment in patient eyes randomized to either the insert plus prn artificial tears or&#xD;
      artificial tears prn control. To aid in ensuring best possible masking, DEXTENZA is best&#xD;
      visualized with blue light and yellow filter and therefore visualization will not be assessed&#xD;
      until final visit following all measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine effect of dexamethasone insert over artificial tears</measure>
    <time_frame>1 month</time_frame>
    <description>To determine the effect of dexamethasone insert plus over-the-counter artificial tears prn compared to over the counter artificial tears prn from Baseline at Week 2 (at 8 am, 12 pm and 4 pm) as measured by iTrace and IOL Master 700: and comfort of dry eyes using the OSDI scale and reading scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OSDI scores</measure>
    <time_frame>1 month</time_frame>
    <description>comfort of dry eyes using the OSDI scale and reading scores, scores are from the SPEED questionnaire. scale from 0-3 0-Never 1- Sometime 2-Often 3-Constant for the symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ITRACE</measure>
    <time_frame>1 month</time_frame>
    <description>measured by iTrace to measure comfort of dry eyes, no scale just review the changes if there are any</description>
  </other_outcome>
  <other_outcome>
    <measure>IOL Master</measure>
    <time_frame>1 month</time_frame>
    <description>as measured by IOL Master 700 to measure comfort of dry eyes, compare the previous images after each visit</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Dextenza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Over the counter Artificial tears</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Intracanalicular Insert</intervention_name>
    <description>all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion</description>
    <arm_group_label>Dextenza</arm_group_label>
    <other_name>dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Over the counter Artificial tears</intervention_name>
    <description>over the counter artificial tears PRN at patient discretion</description>
    <arm_group_label>Over the counter Artificial tears</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:A patient's study eye must meet the following criteria to be eligible&#xD;
        for inclusion in the study:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Demonstrate objective signs of Ocular Surface Disease (OSD) or&#xD;
&#xD;
          -  Demonstrate symptoms of OSD determined by a standardized questionnaire&#xD;
&#xD;
          -  No other corneal pathology to create unknown variability&#xD;
&#xD;
        Exclusion Criteria:A patient who meets any of the following criteria in either eye will be&#xD;
        excluded from the study:&#xD;
&#xD;
          -  History of using topical steroids or other anti-inflammatory drops within 6 months of&#xD;
             the study&#xD;
&#xD;
          -  History of corticosteroid implant (Ozurdex or Iluvien) or intravitreal steroid use for&#xD;
             macular disease in last 12 months&#xD;
&#xD;
          -  History or current use of oral steroids or immunosuppressants&#xD;
&#xD;
          -  Active ocular infection&#xD;
&#xD;
          -  History of HSV&#xD;
&#xD;
          -  History corneal refractive surgery&#xD;
&#xD;
          -  Uncontrolled Glaucoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inder P Singh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>President</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pam Lightfield</last_name>
    <phone>(262) 637-0500</phone>
    <phone_ext>5677</phone_ext>
    <email>plightfield@amazingeye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Eye Center of Racine</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Lightfield</last_name>
      <phone>262-637-0500</phone>
      <phone_ext>5677</phone_ext>
      <email>plightfield@amazingeye.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Eye Centers of Racine and Kenosha</investigator_affiliation>
    <investigator_full_name>Pam Lightfield</investigator_full_name>
    <investigator_title>I. Paul Singh, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

